Compare Constellation Energy Corporation (CEG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Constellation Energy Corporation trades at $279.67 (market cap $98.63B), while State Street SPDR S&P Biotech ETF trades at $158.94. The key difference: Constellation Energy Corporation pays a 0.61% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Constellation Energy Corporation nearer its low. Which is the better fit depends on your goals.
| CEG | XBI | |
|---|---|---|
Market Cap | $98.63B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $403.95 | $164.28 |
52-Week Low | $236.50 | $86.92 |
Enterprise Value | $122.63B | — |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $279.75, up 3.45% in the past 24 hours, with a bullish technical signal and strong support near $277. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised 2026 guidance, driven by nuclear power demand and new contracts like the Walmart PPA. Revenue growth is robust, with 2026 projections at $31.3 billion, and profitability metrics show a net margin of 11.08% and ROE of 15.26%.
The outlook is positive, with a consensus price target of $332.13 implying 19% upside, supported by AI-driven electricity demand and nuclear fleet advantages. Risks include execution challenges in integrating acquisitions and potential regulatory shifts. Analysts are bullish, with 70% buy ratings, citing long-term growth from data center power needs.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
